Advertisement

International Journal of Clinical Oncology

, Volume 24, Issue 10, pp 1320–1327 | Cite as

A single-arm, phase 2 study of steroid-containing mouthwash for the prevention of everolimus-associated stomatitis in multiple tumor types

  • Masaya HattoriEmail author
  • Sumitaka Hagiwara
  • Haruru Kotani
  • Michiko Tatematsu
  • Masahiko Tachi
  • Susumu Hijioka
  • Junichi Shimizu
  • Masashi Andoh
  • Yasunari Mizuno
  • Masataka Sawaki
  • Akiyo Yoshimura
  • Naomi Gondo
  • Yayoi Adachi
  • Kenichi Yoshimura
  • Hiroji Iwata
Original Article
  • 127 Downloads

Abstract

Background

Everolimus is a mammalian target of rapamycin inhibitor used in the treatment of multiple tumor types, and its most common toxicity, stomatitis, can affect patient quality of life. Recent studies in breast cancer have supported the efficacy of steroid mouthwash for the prevention of everolimus-associated stomatitis. However, a few studies have been reported to date, and none have examined this effect in other tumor types.

Methods

This single-arm phase 2 study was designed to evaluate the efficacy of steroid-containing mouthwash for the prevention of stomatitis in patients with multiple tumor types receiving everolimus. The primary outcome was incidence of grade ≥ 2 stomatitis at 8 weeks of everolimus with steroid-containing mouthwash prophylaxis. We also assessed the stability of steroid-containing mouthwash components.

Results

Twenty-nine patients were evaluated, of which 76% had breast cancer and 24% had neuroendocrine tumors originating in the lung, gastrointestinal tract, pancreas, or of unknown primary origin. Grade ≥ 2 stomatitis incidence at 8 weeks was 28.1% (90% CI 16.2–46.1); the higher confidence limit exceeded the prespecified threshold of 30%. No patients developed grade ≥ 3 stomatitis. Most stomatitis occurred behind the oral cavity, with no lesions observed on the lips or floor of the mouth.

Conclusions

Our findings did not support a prophylactic effect of steroid-containing mouthwash on everolimus-associated stomatitis. Given the needs of prevention of everolimus-associated stomatitis in various tumor types, further studies in a larger population using a randomized controlled trial design are, therefore, required to confirm the efficacy of steroid-containing mouthwash.

Keywords

Steroid-containing mouthwash Breast cancer Neuroendocrine tumors Everolimus Prophylaxis Stomatitis 

Notes

Acknowledgements

We thank Edanz Group for English editing a draft of this manuscript.

Author contributions

M.H.: conceptualization, data curation, formal analysis, investigation, resources and writing—original draft, and writing—review and editing. S.H.: formal analysis, data curation, investigation, methodology, and writing—review and editing. H.K.: project administration, investigation, resources, and methodology. M.T.: investigation, methodology, and resources. M.T.: data curation, formal analysis, methodology, investigation, writing—original draft, and writing—review and editing. S.H.: investigation, resources, supervision, and writing—review and editing. J.S.: investigation, resources, supervision, and writing—review and editing. M.A.: resources, supervision, and writing—review and editing. Y.M.: investigation, methodology, and resources. M.S.: investigation and resources. A.Y.: investigation and resources. N.G.: investigation and resources. Y.A.: investigation and resources. K.Y.: formal analysis, methodology, and supervision. H.I.: conceptualization, supervision, and writing—review and editing.

Funding

No specific funding has been provided for this study.

Compliance with ethical standards

Conflict of interest

Masaya Hattori received honoraria from Chugai Pharmaceutical, Eli Lilly Japan, Novartis Pharma, AstraZeneca, Pfizer Japan, and Eisai for work performed outside of the current study. Susumu Hijioka received honoraria from Novel Pharma, Novartis Pharma, and Tenjin Pharma for work performed outside of the current study. Hiroji Iwata received research funding from Chugai Pharmaceutical, MSD K.K, Eli Lilly Japan, and Novartis Pharma for work performed outside of the current study; received honoraria from Chugai Pharmaceutical, Daiichi Sankyo, and AstraZeneca for work performed outside of the current study; and is a member of scientific advisory board of Daiichi Sankyo, Chugai Pharmaceutical, Eli Lilly Japan, Kyowa Hakko Kirin, Pfizer Japan, Novartis Pharma, and AstraZeneca for work performed outside of the current study. The other authors have no conflicts of interest to declare.

Supplementary material

10147_2019_1476_MOESM1_ESM.docx (371 kb)
Supplementary material 1 (DOCX 371 kb)

References

  1. 1.
    Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449–456.  https://doi.org/10.1016/S0140-6736(08)61039-9 CrossRefGoogle Scholar
  2. 2.
    Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514–523.  https://doi.org/10.1056/NEJMoa1009290 CrossRefGoogle Scholar
  3. 3.
    Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520–529.  https://doi.org/10.1056/NEJMoa1109653 CrossRefGoogle Scholar
  4. 4.
    Yao JC, Fazio N, Singh S et al (2016) Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387(10022):968–977.  https://doi.org/10.1016/S0140-6736(15)00817-X CrossRefGoogle Scholar
  5. 5.
    Martins F, de Oliveira MA, Wang Q et al (2013) A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol 49(4):293–298.  https://doi.org/10.1016/j.oraloncology.2012.11.008 CrossRefGoogle Scholar
  6. 6.
    Rugo HS, Hortobagyi GN, Yao J et al (2016) Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. Ann Oncol 27(3):519–525.  https://doi.org/10.1093/annonc/mdv595 CrossRefGoogle Scholar
  7. 7.
    Rugo HS, Seneviratne L, Beck JT et al (2017) Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol.  https://doi.org/10.1016/s1470-2045(17)30109-2 Google Scholar
  8. 8.
    Jones VE, McIntyre KJ, Paul D et al (2019) Evaluation of miracle mouthwash plus hydrocortisone versus prednisolone mouth rinses as prophylaxis for everolimus-associated stomatitis: a randomized phase II study. Oncologist.  https://doi.org/10.1634/theoncologist.2018-0340 Google Scholar
  9. 9.
    Yardley DA, Noguchi S, Pritchard KI et al (2013) Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 30(10):870–884.  https://doi.org/10.1007/s12325-013-0060-1 CrossRefGoogle Scholar
  10. 10.
    Noguchi S, Masuda N, Iwata H et al (2014) Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2. Breast Cancer 21(6):703–714.  https://doi.org/10.1007/s12282-013-0444-8 CrossRefGoogle Scholar
  11. 11.
    Rugo HS, Pritchard KI, Gnant M et al (2014) Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol 25(4):808–815.  https://doi.org/10.1093/annonc/mdu009 CrossRefGoogle Scholar
  12. 12.
    Ito T, Okusaka T, Ikeda M et al (2012) Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial. Jpn J Clin Oncol 42(10):903–911.  https://doi.org/10.1093/jjco/hys123 CrossRefGoogle Scholar
  13. 13.
    Toi M, Masuda N, Andre F et al (2013) Everolimus plus trastuzumab and vinorelbine in Asian patients with HER2-positive metastatic breast cancer. In: Thirty-sixth annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio.  https://doi.org/10.1158/0008-5472.sabcs13-p4-12-19. Published December 2013
  14. 14.
    Toyama T, Jeong J, Srimuninnimit V et al (2017) Everolimus (EVE)+ letrozole (LET) in Asian patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): results of a subgroup analysis from the BOLERO-4 study. In: ESMO Asia, Singapore.  https://doi.org/10.1093/annonc/mdx654
  15. 15.
    Niikura N, Nakatukasa K, Amamiya T, Watanabe K-i, Hata H, Kikawa Y, Taniike N, Yamanaka T, Mitsunaga S, Nakagami K, Adachi M, Kondo N, Horii K, Hayashi N, Naito M, Kashiwabara K, Yamashita T, Umeda M, Mukai H, Ota Y (2019) Abstract P1–11-01: oral care evaluation to prevent oral mucositis in estrogen receptor positive metastatic breast cancer patients treated with everolimus (Oral Care-BC): a randomized controlled phase III trial. Cancer Res 79(4):P1-11-01-P11-11-01.  https://doi.org/10.1158/1538-7445.sabcs18-p1-11-01 Google Scholar
  16. 16.
    Sonis ST, Tracey C, Shklar G et al (1990) An animal model for mucositis induced by cancer chemotherapy. Oral Surg Oral Med Oral Pathol 69(4):437–443CrossRefGoogle Scholar
  17. 17.
    Rubenstein EB, Peterson DE, Schubert M et al (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100(9 Suppl):2026–2046.  https://doi.org/10.1002/cncr.20163 CrossRefGoogle Scholar
  18. 18.
    Steven KH (1997) Adrenal cortical steroids. Drug facts and comparisons, 5th edn. Facts and Comparisons, Inc., St. LouisGoogle Scholar
  19. 19.
    Sonis S, Treister N, Chawla S et al (2010) Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 116(1):210–215.  https://doi.org/10.1002/cncr.24696 Google Scholar
  20. 20.
    Boers-Doets CB, Epstein JB, Raber-Durlacher JE et al (2012) Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist 17(1):135–144.  https://doi.org/10.1634/theoncologist.2011-0111 CrossRefGoogle Scholar
  21. 21.
    Meiller TF, Varlotta S, Weikel D (2015) Recognition and management of oral mucosal injury caused by mammalian target of rapamycin inhibitors: a case series. Case Rep Oncol 8(2):369–377.  https://doi.org/10.1159/000438747 CrossRefGoogle Scholar
  22. 22.
    Peterson DE, O’Shaughnessy JA, Rugo HS et al (2016) Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice. Cancer Med 5(8):1897–1907.  https://doi.org/10.1002/cam4.761 CrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2019

Authors and Affiliations

  • Masaya Hattori
    • 1
    Email author
  • Sumitaka Hagiwara
    • 2
  • Haruru Kotani
    • 1
  • Michiko Tatematsu
    • 3
  • Masahiko Tachi
    • 4
  • Susumu Hijioka
    • 5
  • Junichi Shimizu
    • 6
  • Masashi Andoh
    • 7
  • Yasunari Mizuno
    • 3
  • Masataka Sawaki
    • 1
  • Akiyo Yoshimura
    • 1
  • Naomi Gondo
    • 1
  • Yayoi Adachi
    • 1
  • Kenichi Yoshimura
    • 8
  • Hiroji Iwata
    • 1
  1. 1.Department of Breast OncologyAichi Cancer CenterNagoyaJapan
  2. 2.Department of Head and Neck SurgeryAichi Cancer CenterNagoyaJapan
  3. 3.Department of PharmacyAichi Cancer CenterNagoyaJapan
  4. 4.Aichi Prefectural Institute of Public HealthNagoyaJapan
  5. 5.Department of Hepatobiliary and Pancreatic OncologyNational Cancer CenterTokyoJapan
  6. 6.Department of Thoracic OncologyAichi Cancer CenterNagoyaJapan
  7. 7.Department of Clinical OncologyAichi Cancer CenterNagoyaJapan
  8. 8.Innovative Clinical Research CenterKanazawa UniversityKanazawaJapan

Personalised recommendations